Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BiomX ( (PHGE) ).
On October 17, 2025, BiomX Inc. announced that the FDA had raised additional questions regarding the nebulizer device used in their Phase 2b study for the drug candidate BX004, aimed at treating Cystic Fibrosis. The company is continuing its study in Europe and plans to incorporate FDA feedback into future development plans, with topline results expected in early 2026.
The most recent analyst rating on (PHGE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing innovative treatments for chronic diseases. The company is primarily engaged in creating phage therapies, with a significant market focus on addressing unmet medical needs in conditions such as Cystic Fibrosis.
Average Trading Volume: 4,149,790
Technical Sentiment Signal: Sell
Current Market Cap: $15.69M
Learn more about PHGE stock on TipRanks’ Stock Analysis page.